Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 1
1990 1
1993 1
1995 1
1996 3
1997 3
1998 10
1999 13
2000 16
2001 13
2002 20
2003 22
2004 39
2005 53
2006 93
2007 118
2008 260
2009 358
2010 464
2011 738
2012 1198
2013 1475
2014 1568
2015 1325
2016 1338
2017 1103
2018 979
2019 1264
2020 1227
2021 965
2022 869
2023 632
2024 178

Text availability

Article attribute

Article type

Publication date

Search Results

13,856 results

Results by year

Filters applied: . Clear all
Page 1
Clinical trial design in the era of precision medicine.
Fountzilas E, Tsimberidou AM, Vo HH, Kurzrock R. Fountzilas E, et al. Genome Med. 2022 Aug 31;14(1):101. doi: 10.1186/s13073-022-01102-1. Genome Med. 2022. PMID: 36045401 Free PMC article. Review.
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Brackman D, Siddani S, Wang J, Chyla B, Lee P, Altman JK. Daver N, et al. J Clin Oncol. 2022 Dec 10;40(35):4048-4059. doi: 10.1200/JCO.22.00602. Epub 2022 Jul 18. J Clin Oncol. 2022. PMID: 35849791 Free PMC article. Clinical Trial.
DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M. Yao J, et al. Oncologist. 2022 Nov 3;27(11):940-951. doi: 10.1093/oncolo/oyac161. Oncologist. 2022. PMID: 35983951 Free PMC article. Review.
Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
Carter BZ, Mak PY, Muftuoglu M, Tao W, Ke B, Pei J, Bedoy AD, Ostermann LB, Nishida Y, Isgandarova S, Sobieski M, Nguyen N, Powell RT, Martinez-Moczygemba M, Stephan C, Basyal M, Pemmaraju N, Boettcher S, Ebert BL, Shpall EJ, Wallner B, Morgan RA, Karras GI, Moll UM, Andreeff M. Carter BZ, et al. Blood. 2023 Sep 21;142(12):1056-1070. doi: 10.1182/blood.2022019047. Blood. 2023. PMID: 37339579
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma.
Scholler N, Perbost R, Locke FL, Jain MD, Turcan S, Danan C, Chang EC, Neelapu SS, Miklos DB, Jacobson CA, Lekakis LJ, Lin Y, Ghobadi A, Kim JJ, Chou J, Plaks V, Wang Z, Xue A, Mattie M, Rossi JM, Bot A, Galon J. Scholler N, et al. Nat Med. 2022 Sep;28(9):1872-1882. doi: 10.1038/s41591-022-01916-x. Epub 2022 Aug 29. Nat Med. 2022. PMID: 36038629 Free PMC article.
Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.
Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR. Westin J, et al. J Clin Oncol. 2023 Feb 1;41(4):745-755. doi: 10.1200/JCO.22.00597. Epub 2022 Aug 11. J Clin Oncol. 2023. PMID: 35952327 Free PMC article.
13,856 results
You have reached the last available page of results. Please see the User Guide for more information.